Literature DB >> 1855215

Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer.

P H Watson1, R T Pon, R P Shiu.   

Abstract

In search of critical genes in the mechanism of estrogen action in human breast cancer, we previously showed that estrogen stimulates transcription of the c-myc gene in estrogen-dependent (MCF-7) cells. We have now examined the role of c-myc in estrogen-stimulated growth of MCF-7 cells through the use of a synthetic antisense c-myc phosphorothioate oligonucleotide to specifically inhibit expression of the c-myc protein. Estrogen induces a 5-fold increase in c-myc protein expression within 90 min in steroid-deprived cells, as detected by Western blot. Prior exposure of MCF-7 cells to 10 microM c-myc antisense oligonucleotide results in up to 95% inhibition of the c-myc protein expression induced by estrogen. Antisense-myc oligonucleotide inhibits estrogen-stimulated cell growth by up to 75% over 9 days and also exerts a cytostatic effect on the growth of estrogen-independent MDA-MB-231 cells which show relatively high, constitutive expression of c-myc. Sense-myc and antisense-pS2 oligonucleotides have no effect on c-myc protein level or growth in either cell line. These results demonstrate both the specific and durable effects of antisense phosphorothioate oligonucleotides. Furthermore, these results indicate a critical role for c-myc in the growth of breast cancer cells and support the hypothesis that loss of estrogen regulation of this gene may be an important factor in the progression of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1855215

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

1.  Growth inhibition of human liver cancer cells by alpha-fetoprotein antisense strategy.

Authors:  X W Wang; H Xie
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999-03       Impact factor: 2.416

2.  Antiproliferative effects of a c-myc antisense oligonucleotide on human arterial smooth muscle cells.

Authors:  M Ebbecke; C Unterberg; A Buchwald; S Stöhr; V Wiegand
Journal:  Basic Res Cardiol       Date:  1992 Nov-Dec       Impact factor: 17.165

3.  The cochaperone p23 differentially regulates estrogen receptor target genes and promotes tumor cell adhesion and invasion.

Authors:  Ellinor Oxelmark; Jennifer M Roth; Peter C Brooks; Steven E Braunstein; Robert J Schneider; Michael J Garabedian
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

4.  c-Myc downregulation: a critical molecular event in resveratrol-induced cell cycle arrest and apoptosis of human medulloblastoma cells.

Authors:  Peng Zhang; Hong Li; Mo-Li Wu; Xiao-Yan Chen; Qing-You Kong; Xiao-Wei Wang; Yuan Sun; Shu Wen; Jia Liu
Journal:  J Neurooncol       Date:  2006-05-25       Impact factor: 4.130

5.  c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry.

Authors:  O W Prall; E M Rogan; E A Musgrove; C K Watts; R L Sutherland
Journal:  Mol Cell Biol       Date:  1998-08       Impact factor: 4.272

6.  A truncated Ah receptor blocks the hypoxia and estrogen receptor signaling pathways: a viable approach for breast cancer treatment.

Authors:  Kyle A Jensen; Tony C Luu; William K Chan
Journal:  Mol Pharm       Date:  2006 Nov-Dec       Impact factor: 4.939

7.  Conserved features of cancer cells define their sensitivity to HAMLET-induced death; c-Myc and glycolysis.

Authors:  P Storm; S Aits; M K Puthia; A Urbano; T Northen; S Powers; B Bowen; Y Chao; W Reindl; D Y Lee; N L Sullivan; J Zhang; M Trulsson; H Yang; J D Watson; C Svanborg
Journal:  Oncogene       Date:  2011-06-06       Impact factor: 9.867

8.  Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression.

Authors:  E A Musgrove; J A Hamilton; C S Lee; K J Sweeney; C K Watts; R L Sutherland
Journal:  Mol Cell Biol       Date:  1993-06       Impact factor: 4.272

9.  ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways.

Authors:  Sheng-Li Lin; Li-Ying Yan; Xin-Tian Zhang; Ju Yuan; Mo Li; Jie Qiao; Zhao-Yi Wang; Qing-Yuan Sun
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

10.  The molecular genetics of breast cancer and targeted therapy.

Authors:  Rachel Suter; James A Marcum
Journal:  Biologics       Date:  2007-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.